Anixa Biosciences Advances Breast Cancer Vaccine to Phase 2 Trials with Cytovance Biologics as cGMP Manufacturer

Anixa Biosciences has announced progress in the development of its breast cancer vaccine, moving toward Phase 2 clinical trials following positive results from Phase 1 testing. The company also confirmed the selection of Cytovance Biologics for cGMP (current Good Manufacturing Practice) manufacturing to support the next stage of the vaccine’s development.

The Phase 1 trial reportedly demonstrated promising safety and efficacy data, which has enabled Anixa Biosciences to advance its investigational vaccine into further clinical evaluation. The vaccine is designed to prevent triple-negative breast cancer, a particularly aggressive form of the disease that lacks targeted treatment options. To facilitate this progression, Cytovance Biologics will handle production under cGMP standards, ensuring compliance with regulatory requirements for pharmaceutical manufacturing. This collaboration marks a critical step in scaling up production as preparations for Phase 2 trials continue.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: April 1, 2026

Author

GOAI